Navigation Links
Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
Date:1/23/2008

preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2007 and quarterly report on Form 10-Q for the quarter ended July 31, 2007. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

Contacts:

GendeLLindheim BioCom Partners

Investors Media

info@peregrineinc.com Barbara Lindheim

(800) 987-8256 (212) 918-4650


'/>"/>
SOURCE Peregrine Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
2. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
3. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
4. Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer
5. Peregrine Pharmaceuticals Doses First Patient in Clinical Trial of Bavituximab in HCV Patients Co-Infected With HIV
6. Peregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
7. New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models
8. Peregrine Announces Addition of The Johns Hopkins Hospital as Study Site for Bavituximab Trial in HCV Patients Co-Infected With HIV
9. Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
10. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Dec. 18, 2014  Sage Analytics ( www.sageanalytics.com ... equipment for the testing of marijuana potency and ... new Luminary™ Profiler, the industry,s first product suite ... a cost-effective, portable unit. Designed from ... of the cannabis industry, the Luminary™ Profiler utilizes ...
(Date:12/19/2014)... Calif., Dec. 18, 2014 Capnia, Inc. ... development of medical diagnostics based on its proprietary ... flow, today announced financial results for the third ... "Following the completion of our initial ... to maximize the recently initiated CoSense® commercial launch," ...
(Date:12/19/2014)... , Dec. 18, 2014 Baptist Health Lexington is ... to receive full Atrial Fibrillation with Electrophysiology Services (EPS) ... Atrial fibrillation is the most common cardiac arrhythmia ... some cases can lead to stroke and possible death. More ... have atrial fibrillation and the numbers are rapidly ...
Breaking Medicine Technology:Sage Analytics Develops Breakthrough System for Potency Testing of Cannabis Products 2Capnia Reports Third Quarter 2014 Financial Results 2Capnia Reports Third Quarter 2014 Financial Results 3Capnia Reports Third Quarter 2014 Financial Results 4Capnia Reports Third Quarter 2014 Financial Results 5Capnia Reports Third Quarter 2014 Financial Results 6Capnia Reports Third Quarter 2014 Financial Results 7Capnia Reports Third Quarter 2014 Financial Results 8Baptist Health Lexington First in the Nation to Receive Atrial Fibrillation with EPS Accreditation 2Baptist Health Lexington First in the Nation to Receive Atrial Fibrillation with EPS Accreditation 3
... Loss, Non-Inferiority in Target Vessel Failure and Low Rates of MACE ... ... PARK, Ill., April 22 A study published,in today,s Journal of ... Everolimus Eluting Coronary Stent System,in patients with coronary artery disease resulted ...
... Data For Presentation At ASCO 2008, LONDON ... a wide range of new data at the ... Chicago starting Friday, May,30th. The data cover a ... treatment and supportive care of cancer,patients. At this ...
Cached Medicine Technology:Study in JAMA Shows Patients Treated With Abbott's XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent 2Study in JAMA Shows Patients Treated With Abbott's XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent 3Study in JAMA Shows Patients Treated With Abbott's XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent 4Study in JAMA Shows Patients Treated With Abbott's XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent 5GlaxoSmithKline Reports Further Progress of Oncology Portfolio 2GlaxoSmithKline Reports Further Progress of Oncology Portfolio 3GlaxoSmithKline Reports Further Progress of Oncology Portfolio 4GlaxoSmithKline Reports Further Progress of Oncology Portfolio 5GlaxoSmithKline Reports Further Progress of Oncology Portfolio 6GlaxoSmithKline Reports Further Progress of Oncology Portfolio 7
(Date:12/22/2014)... 2014 Coral Gables is preparing to welcome ... Troopers, with its new clinic location set to open in ... hassle out of dealing with this common childhood parasite by ... two salon clinic locations in South Florida, or in the ... decision to expand developed naturally out of the demand for ...
(Date:12/22/2014)... New York (PRWEB) December 22, 2014 The ... a staple of the season. Many may be thinking about ... a span of a few weeks. Health Republic Insurance of ... of Registered Dietitian, Andrea Chernus, to provide some smart ideas ... and stay healthy. , 1)    Avoid arriving at a holiday gathering ...
(Date:12/22/2014)... Shanghai, China (PRWEB) December 22, 2014 ... for MabThera (rituximab) for the treatment of non-Hodgkin’s lymphoma ... Health , a leading global healthcare consulting firm. MabThera ... B-cell lymphoma (DLBCL), the most common form of NHL. ... Market Access and Barriers,” the incidence of NHL in ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 Only weeks ... southern and mid-western cities to have a battery manufacturer ... TalkLocal ( http://www.talklocal.com ) is launching in Henderson ... economy. , “A strong manufacturing sector is going ... founder Gurpreet Singh explained, “and TalkLocal works with small ...
(Date:12/22/2014)... 2014 Pasadena sleep apnea ... sleep apnea. Drowsy drivers are 15 times more likely ... well-rested, and some experts believe that sleep-deprived drivers may ... drivers. Unfortunately, millions of Americans may be sleep-deprived without ... Sleep Medicine, about 18 million Americans have sleep apnea, ...
Breaking Medicine News(10 mins):Health News:Professional In-Home All-Natural Lice Removal Service Expands to Coral Gables and surrounding areas. 2Health News:Health Republic Insurance of New York Offers Five Simple Tips to Eat Healthy During the Holidays 2Health News:Physicians in China See Most Significant Demand for MabThera Biosimilar 2Health News:Physicians in China See Most Significant Demand for MabThera Biosimilar 3Health News:TalkLocal Launches in Henderson Weeks Following New Megafactory, New Jobs Announcement 2Health News:Pasadena Dentist, Dr. Marine Martirosyan, Now Offers Consultations for Sleep Apnea 2
... offers 50 percent smaller size, 20 percent less ... in portable equipment, DALLAS, March 24 ... market, Texas Instruments (TI) (NYSE: TXN ),today ... ends (AFEs) for,portable to high-end ultrasound diagnostic equipment. ...
... Medicare & Medicaid Services Accepts as Complete DNV,s ... Application for Hospital Deeming Authority, HOUSTON, March ... has informed DNV Healthcare that its application to,deem hospitals in ... complete and ready for formal review., If approved, DNV ...
... and vision care with ... medical coverage, DETROIT, March ... all rolled into one product package., The "package" is Community Blue ... that will launch April 1. Community,Blue Plus combines preventive dental and vision ...
... Health care facilities, like all,Pennsylvania businesses, strive ... reducing workers, compensation expenses driven by claims made,against ... challenges,in the frequency and types of on the ... based law firm of Fried, Kane, Walters, Zuschlag,and ...
... and dementia patients and ... families regain what was once ... million Americans,including 250,000 Ohioans, struggle with the devastating effects ... the greater,Cleveland area offers new hope to Alzheimer,s patients ...
... -- Sinovac Biotech Ltd. (Amex:,SVA), a leading provider of ... Ms. Nan Wang, Vice President, Ms. Helen Yang,International Business ... at the Brean Murray, Carret & Co. Fourth Investor ... p.m. China Standard Time at the,Grand Hyatt Hotel in ...
Cached Medicine News:Health News:Video: TI unveils industry's first family of complete analog front ends for superior ultrasound systems 2Health News:Video: TI unveils industry's first family of complete analog front ends for superior ultrasound systems 3Health News:Video: TI unveils industry's first family of complete analog front ends for superior ultrasound systems 4Health News:DNV Healthcare Advances in Bid to Accredit Hospitals 2Health News:Blue Cross Blue Shield of Michigan Pioneers 'Total Body' PPO Product 2Health News:Reducing Cost of Health Care by Addressing Workers' Compensation Costs 2Health News:Cleveland Area Homewatch CareGivers Unveil New Alzheimer's Program 2Health News:Sinovac to Present at the Brean Murray, Carret & Co. Fourth Investor Tour of China 2
Inquire...
Inquire...
... X-22 Series is up to 10 inches/ 25 cm ... 11 rotors, the Allegra X-22 Series is the space-saving ... Only 18 inches / 46 cm wide • 11 ... 3 different ways to Spin 1.5 mL & ...
... Optimal for Subcellular Fractionation, Proteins ... g (30,000 rpm) with fixed-angle ... 0.25 up to 85 mL ... C to 40° C • ...
Medicine Products: